Navigation Links
Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
Date:2/12/2013

n the United States there are approximately 1,500 new cases each year.

About Ibrutinib
Ibrutinib is an investigational drug designed to specifically target and selectively inhibit an enzyme called Bruton's tyrosine kinase (BTK). BTK is a key mediator of at least three critical B-cell pro-survival mechanisms occurring in parallel – regulating apoptosis, adhesion, and cell migration and homing. Through these multiple actions, BTK helps to direct malignant B-cells to lymphoid tissues, thus allowing access to a micro environment necessary for survival.

The effectiveness and safety of ibrutinib alone or in combination with other treatments is being studied in several B-cell malignancies, including chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, Waldenstrom's macroglobulinemia and multiple myeloma. To date five Phase III trials have been initiated with ibrutinib and a total of 27 trials are currently registered on clinicaltrials.gov.

About Pharmacyclics
Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medical healthcare needs; and to identify promising product candidates based on scientific development and administrational expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently, Pharmacyclics has three product candidates in clinical development and several preclinical molecules in lead optimization.
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
2. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
3. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
4. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
5. Landauer, Inc. Reports Fiscal 2013 First Quarter Results
6. Misonix Reports Financial Results for First Half of Fiscal 2013
7. CareFusion Reports First Half Fiscal 2013 Results
8. Avanir Pharmaceuticals Reports Fiscal 2013 First Quarter Financial And Business Results
9. American Pacific Reports Fiscal 2013 First Quarter Results; Reaffirms Full Year Guidance
10. European patient registry in venous thromboembolism (VTE) - PREFER in VTE - enrols first patient
11. Neutronic Ear Introduces Worlds First Rechargeable-Powered Hearing Device
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... FRANKLIN, Ohio , Jan. 15, 2014  A novel wearable ... it easy and painless for patients to self-inject prescription drugs ... of disorders, including cancer, blood diseases, autoimmune deficiencies, and genetic ... expected to grow to $220B by 2018, according to analysts.   ...
(Date:1/14/2014)... Healthcare Services, Inc. ("DHS"), a portfolio company of GMH Ventures ... Equipment, Inc. ("Progressive") of Clarion, PA ... not disclosed. Progressive is a full service ... sleep, mobility, and respiratory products to customers in the western ...
(Date:1/14/2014)... N.Y. , Jan. 14, 2014   Oligomerix, Inc. , ... modifying therapeutics for Alzheimer,s disease (AD) and related neurodegenerative ... to Valhalla, NY as of ... laboratory space at New York Medical College. ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... MEETING, Pa., Nov. 8, 2010 Keeping radiation ... hospitals, particularly in computed tomography (CT), which has undergone some ... side is that CT delivers some of the highest radiation ... measures for delivering the appropriate radiation dose can result in ...
... Biotechnologies Corporation, a leader in the emerging field of ... financial support for the company,s lead oncology product, Rexin-G, ... Services (HHS), and the National Institutes of Health (NIH) ... latest support for the clinical advancement of Rexin-G comes ...
Cached Medicine Technology:ECRI Institute Service to Address CT Radiation Dose Safety 2ECRI Institute Service to Address CT Radiation Dose Safety 3Epeius Biotechnologies Awarded Federal Grant Advancing Tumor-Targeted Cancer Therapy 2
(Date:4/24/2014)... me out to the ballgame, doesn,t exactly conjure up ... likely culprits include French fries, soda and the occasional ... play youth baseball, eating unhealthy food during practices and ... researchers at Wake Forest Baptist Medical Center. The study, ... Obesity , found that high-calorie snacks and sugar-sweetened drinks ...
(Date:4/24/2014)... the relevance of palliation in advanced cancer are ... trials (RCTs). This is the result of an ... Efficiency in Health Care (IQWiG), which has now ... external experts, IQWiG analysed studies on four solid ... and pancreatic cancer. For this purpose, the research ...
(Date:4/24/2014)... one of 30 grants from the National Cancer Institute ... in its new National Clinical Trials Network ... investigators charged with distributing resources in a more effective ... reflects recommendations from a 2010 Institute of Medicine ... Faster design, launch, and completion of clinical ...
(Date:4/23/2014)... pilot study by Massachusetts General Hospital (MGH) investigators may ... treatment for a serious medical problem use of ... caused by the Clostridium difficile ( C. ... online in the journal Clinical Infectious Diseases , ... material from donors unrelated to patients was as successful ...
(Date:4/23/2014)... M.D., scientific director at the National Institute of Arthritis ... the 2014 recipient of the Ross Prize in Molecular ... Molecular Medicine . The award will be given ... Sciences in Manhattan, followed by scientific presentations by Dr. ... the National Institutes of Health. , The award, which ...
Breaking Medicine News(10 mins):Health News:Take the bat, leave the candy 2Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3Health News:Dartmouth awarded lead role in NCI clinical trials network 2Health News:Dartmouth awarded lead role in NCI clinical trials network 3Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 2Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 3Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2
... and dairy products, study finds, , FRIDAY, June 26 ... products can increase your risk for pancreatic cancer, researchers ... cancer, which is usually fatal, is the fourth-leading cause ... factors for developing the disease have been identified, including ...
... Calif., June 26 Discus Dental, LLC ("Discus") today announced ... court against Florida-based BSML, Inc. ("BSML") charging BSML with breach ... its lawsuit, Discus seeks to end a license agreement with ... order prohibiting BSML from future use of the trademark, and ...
... of Company Exemplifies the Best in Retirement Living , , ... housing will outpace supply in the coming years. Couple that trend with ... the senior housing industry looks very different than it did a decade ... Living, a national leader in senior living ...
... breach of contract , , DALLAS, June 26 A ... two years ago won again Thursday, when an appellate court affirmed ... Court of Appeals for the Fifth District of Texas at Dallas ... 2007 judgment against Pinnacle Anesthesia Consultants, P.A., which provides obstetric anesthesiology ...
... , NEW YORK, June 26 Selecciones , ... the American Heart Association,s (AHA) Go Red For ... retailers, for a second consecutive year in the multi-platform awareness program, ... to the threat of heart disease. , , To ...
... deadlier than a heart attack, experts say, with chances for ... star Michael Jackson probably did not die on Thursday of ... sudden cardiac arrest, experts say. , It,s not yet clear ... Angeles home, but that assumption has been made by many ...
Cached Medicine News:Health News:Eating Animal Fat May Lead to Pancreatic Cancer 2Health News:Eating Animal Fat May Lead to Pancreatic Cancer 3Health News:Discus Dental Files Suit to Protect BriteSmile(R) Trademark 2Health News:Aegis Living Was Created To Place People First in Senior and Assisted Living Communities 2Health News:Aegis Living Was Created To Place People First in Senior and Assisted Living Communities 3Health News:Appeals Court OKs Multimillion-Dollar Judgment for Dallas Doctor 2Health News:Photos: Selecciones, Reader's Digest, The American Heart Association's Go Red For Women and Macy's Reach Hispanic Women With Message of Heart Health 2Health News:Jackson's Death Puts Spotlight on Sudden Cardiac Arrest 2Health News:Jackson's Death Puts Spotlight on Sudden Cardiac Arrest 3
Open blade design with aspiration capabilities for removing fluids from the operative site. 19 gauge wire....
Designed to provide open approaches of the keratome to the cornea for either the left or right eye. Lightweight wire design adds to the comfort of the instrument when in place....
Solid 14 mm free-swinging blades, suture posts, and stabilizing disk. Dull finish....
Designed for use with foster enucleation snare (E3670). Package of 12 stainless steel wires. Overall length 5.3 inches....
Medicine Products: